{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T08:48:39Z","timestamp":1770281319882,"version":"3.49.0"},"publisher-location":"Singapore","reference-count":91,"publisher":"Springer Nature Singapore","isbn-type":[{"value":"9789819913039","type":"print"},{"value":"9789819913046","type":"electronic"}],"license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023]]},"DOI":"10.1007\/978-981-99-1304-6_15","type":"book-chapter","created":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T07:03:20Z","timestamp":1684911800000},"page":"215-226","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Treatment of Hepatitis E"],"prefix":"10.1007","author":[{"given":"Wei","family":"Hui","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linlin","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,5,25]]},"reference":[{"key":"15_CR1","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1111\/jvh.13456","volume":"28","author":"M Gorris","year":"2021","unstructured":"Gorris M et al (2021) Treatment for chronic hepatitis E virus infection: a systematic review and meta-analysis. J Viral Hepat 28:454\u2013463. https:\/\/doi.org\/10.1111\/jvh.13456","journal-title":"J Viral Hepat"},{"key":"15_CR2","doi-asserted-by":"publisher","first-page":"5543","DOI":"10.3748\/wjg.v26.i37.5543","volume":"26","author":"AT Aslan","year":"2020","unstructured":"Aslan AT, Balaban HY (2020) Hepatitis E virus: epidemiology, diagnosis, clinical manifestations, and treatment. World J Gastroenterol 26:5543\u20135560. https:\/\/doi.org\/10.3748\/wjg.v26.i37.5543","journal-title":"World J Gastroenterol"},{"key":"15_CR3","doi-asserted-by":"publisher","first-page":"331","DOI":"10.3390\/jcm9020331","volume":"9","author":"S Lhomme","year":"2020","unstructured":"Lhomme S et al (2020) Clinical manifestations, pathogenesis and treatment of hepatitis E virus infections. J Clin Med 9:331. https:\/\/doi.org\/10.3390\/jcm9020331","journal-title":"J Clin Med"},{"issue":"Suppl 1","key":"15_CR4","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/liv.14351","volume":"40","author":"H Larrue","year":"2020","unstructured":"Larrue H, Abravanel F, P\u00e9ron JM (2020) Hepatitis E, what's the real issue? Liver Int 40(Suppl 1):43\u201347. https:\/\/doi.org\/10.1111\/liv.14351","journal-title":"Liver Int"},{"key":"15_CR5","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1001\/jama.2019.21495","volume":"323","author":"AN Desai","year":"2020","unstructured":"Desai AN, Hepatitis E (2020) JAMA 323:1862. https:\/\/doi.org\/10.1001\/jama.2019.21495","journal-title":"JAMA"},{"key":"15_CR6","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1111\/j.1572-0241.2006.00416.x","volume":"101","author":"TN Chau","year":"2006","unstructured":"Chau TN et al (2006) Epidemiology and clinical features of sporadic hepatitis E as compared with hepatitis A. Am J Gastroenterol 101:292\u2013296. https:\/\/doi.org\/10.1111\/j.1572-0241.2006.00416.x","journal-title":"Am J Gastroenterol"},{"key":"15_CR7","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1046\/j.1365-2893.1998.00096.X","volume":"5","author":"VA Arankalle","year":"1998","unstructured":"Arankalle VA et al (1998) Role of immune serum globulins in pregnant women during an epidemic of hepatitis E. J Viral Hepat 5:199\u2013204. https:\/\/doi.org\/10.1046\/j.1365-2893.1998.00096.X","journal-title":"J Viral Hepat"},{"key":"15_CR8","first-page":"113","volume":"11","author":"MS Khuroo","year":"1992","unstructured":"Khuroo MS, Dar MY (1992) Hepatitis E: evidence for person-to-person transmission and inability of low dose immune serum globulin from an Indian source to prevent it. Indian J Gastroenterol 11:113\u2013116. PMID: 1506045.","journal-title":"Indian J Gastroenterol"},{"key":"15_CR9","doi-asserted-by":"publisher","first-page":"285","DOI":"10.4254\/wjh.v3.i12.285","volume":"3","author":"EH Teshale","year":"2011","unstructured":"Teshale EH, Hu DJ (2011) Hepatitis E: epidemiology and prevention. World J Hepatol 3:285\u2013291. https:\/\/doi.org\/10.4254\/wjh.v3.i12.285","journal-title":"World J Hepatol"},{"key":"15_CR10","doi-asserted-by":"publisher","first-page":"343","DOI":"10.5501\/wjv.v4.i4.343","volume":"4","author":"GY Lee","year":"2015","unstructured":"Lee GY et al (2015) Hepatitis E virus infection: epidemiology and treatment implications. World J Virol 4:343\u2013355. https:\/\/doi.org\/10.5501\/wjv.v4.i4.343","journal-title":"World J Virol"},{"key":"15_CR11","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1016\/j.jhep.2018.03.005","volume":"68","author":"European Association for the Study of the Liver","year":"2018","unstructured":"European Association for the Study of the Liver (2018) EASL clinical practice guidelines on hepatitis E virus infection. J Hepatol 68:1256\u20131271. https:\/\/doi.org\/10.1016\/j.jhep.2018.03.005","journal-title":"J Hepatol"},{"key":"15_CR12","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1016\/j.jhep.2012.05.010","volume":"57","author":"A Del Bello","year":"2012","unstructured":"Del Bello A et al (2012) Hepatitis E virus-induced severe myositis. J Hepatol 57:1152\u20131153. https:\/\/doi.org\/10.1016\/j.jhep.2012.05.010","journal-title":"J Hepatol"},{"key":"15_CR13","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jcv.2011.06.004","volume":"52","author":"R Gerolami","year":"2011","unstructured":"Gerolami R et al (2011) Treatment of severe acute hepatitis E by ribavirin. J Clin Virol 52:60\u201362. https:\/\/doi.org\/10.1016\/j.jcv.2011.06.004","journal-title":"J Clin Virol"},{"key":"15_CR14","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1016\/j.jhep.2011.01.009","volume":"54","author":"JM Peron","year":"2011","unstructured":"Peron JM et al (2011) Acute autochthonous hepatitis E in western patients with underlying chronic liver disease: a role for ribavirin? J Hepatol 54:1323\u20131324. https:\/\/doi.org\/10.1016\/j.jhep.2011.01.009","journal-title":"J Hepatol"},{"key":"15_CR15","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1111\/liv.12114","volume":"33","author":"S Pischke","year":"2013","unstructured":"Pischke S et al (2013) Ribavirin treatment of acute and chronic hepatitis E: a single-centre experience. Liver Int 33:722\u2013726. https:\/\/doi.org\/10.1111\/liv.12114","journal-title":"Liver Int"},{"key":"15_CR16","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1097\/MCG.0000000000000113","volume":"49","author":"M Riveiro-Barciela","year":"2015","unstructured":"Riveiro-Barciela M et al (2015) Phylogenetic demonstration of hepatitis E infection transmitted by pork meat ingestion. J Clin Gastroenterol 49:165\u2013168. https:\/\/doi.org\/10.1097\/MCG.0000000000000113","journal-title":"J Clin Gastroenterol"},{"key":"15_CR17","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.jcv.2014.05.003","volume":"60","author":"A Robbins","year":"2014","unstructured":"Robbins A et al (2014) Severe acute hepatitis E in an HIV infected patient: Successful treatment with ribavirin. J Clin Virol 60:422\u2013423. https:\/\/doi.org\/10.1016\/j.jcv.2014.05.003","journal-title":"J Clin Virol"},{"key":"15_CR18","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s12985-020-01343-9","volume":"17","author":"C Wu","year":"2020","unstructured":"Wu C, Wu X, Xia J (2020) Hepatitis E virus infection during pregnancy. Virol J 17:73. https:\/\/doi.org\/10.1186\/s12985-020-01343-9","journal-title":"Virol J"},{"key":"15_CR19","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1080\/17474124.2019.1568869","volume":"13","author":"P Kar","year":"2019","unstructured":"Kar P, Sengupta A (2019) A guide to the management of hepatitis E infection during pregnancy. Expert Rev Gastroenterol Hepatol 13:205\u2013211. https:\/\/doi.org\/10.1080\/17474124.2019.1568869","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"15_CR20","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1128\/CMR.00057-13","volume":"27","author":"N Kamar","year":"2014","unstructured":"Kamar N et al (2014) Hepatitis E virus infection. Clin Microbiol Rev 27:116\u2013138. https:\/\/doi.org\/10.1128\/CMR.00057-13","journal-title":"Clin Microbiol Rev"},{"key":"15_CR21","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/872431","volume":"2015","author":"A Ahmed","year":"2015","unstructured":"Ahmed A et al (2015) Mystery of hepatitis E virus: recent advances in its diagnosis and management. Int J Hepatol 2015:872431. https:\/\/doi.org\/10.1155\/2015\/872431","journal-title":"Int J Hepatol"},{"key":"15_CR22","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1097\/TP.0b013e3181c4096c","volume":"89","author":"N Kamar","year":"2010","unstructured":"Kamar N et al (2010) Influence of immunosuppressive therapy on the natural history of genotype 3 hepatitis-E virus infection after organ transplantation. Transplantation 89:353\u2013360. https:\/\/doi.org\/10.1097\/TP.0b013e3181c4096c","journal-title":"Transplantation"},{"key":"15_CR23","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1136\/gutjnl-2016-312040","volume":"65","author":"J Gouttenoire","year":"2016","unstructured":"Gouttenoire J, Szkolnicka D, Moradpour D (2016) Treatment of chronic hepatitis E with ribavirin: lessons from deep sequencing. Gut 65:1583\u20131584. https:\/\/doi.org\/10.1136\/gutjnl-2016-312040","journal-title":"Gut"},{"key":"15_CR24","doi-asserted-by":"publisher","first-page":"348","DOI":"10.6002\/ect.2015.0343","volume":"16","author":"KH Hillebrandt","year":"2018","unstructured":"Hillebrandt KH et al (2018) Acute graft dysfunction 17 years after liver transplant: a challenging clinical and histologic manifestation of hepatitis E. Exp Clin Transplant 16:348\u2013351. https:\/\/doi.org\/10.6002\/ect.2015.0343","journal-title":"Exp Clin Transplant"},{"key":"15_CR25","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1111\/jvh.12403","volume":"22","author":"AM Peters van Ton","year":"2015","unstructured":"Peters van Ton AM, Gevers TJ, Drenth JP (2015) Antiviral therapy in chronic hepatitis E: a systematic review. J Viral Hepat 22:965\u2013973. https:\/\/doi.org\/10.1111\/jvh.12403","journal-title":"J Viral Hepat"},{"key":"15_CR26","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1053\/j.gastro.2010.08.002","volume":"139","author":"N Kamar","year":"2010","unstructured":"Kamar N et al (2010) Ribavirin therapy inhibits viral replication on patients with chronic hepatitis e virus infection. Gastroenterology 139:1612\u20131618. https:\/\/doi.org\/10.1053\/j.gastro.2010.08.002","journal-title":"Gastroenterology"},{"key":"15_CR27","doi-asserted-by":"publisher","first-page":"85","DOI":"10.7326\/0003-4819-153-2-201007200-00257","volume":"153","author":"V Mallet","year":"2010","unstructured":"Mallet V et al (2010) Brief communication: case reports of ribavirin treatment for chronic hepatitis E. Ann Intern Med 153:85\u201389. https:\/\/doi.org\/10.7326\/0003-4819-153-2-201007200-00257","journal-title":"Ann Intern Med"},{"key":"15_CR28","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1053\/j.gastro.2011.02.050","volume":"140","author":"N Kamar","year":"2011","unstructured":"Kamar N et al (2011) Factors associated with chronic hepatitis in patients with hepatitis E virus infection who have received solid organ transplants. Gastroenterology 140:1481\u20131489. https:\/\/doi.org\/10.1053\/j.gastro.2011.02.050","journal-title":"Gastroenterology"},{"key":"15_CR29","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1056\/NEJMoa1215246","volume":"370","author":"N Kamar","year":"2014","unstructured":"Kamar N et al (2014) Ribavirin for chronic hepatitis E virus infection in transplant recipients. N Engl J Med 370:1111\u20131120. https:\/\/doi.org\/10.1056\/NEJMoa1215246","journal-title":"N Engl J Med"},{"key":"15_CR30","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1002\/lt.22014","volume":"16","author":"EB Haagsma","year":"2010","unstructured":"Haagsma EB et al (2010) Treatment of chronic hepatitis E in liver transplant recipients with pegylated interferon alpha-2b. Liver Transpl 16:474\u2013477. https:\/\/doi.org\/10.1002\/lt.22014","journal-title":"Liver Transpl"},{"key":"15_CR31","doi-asserted-by":"publisher","first-page":"e30","DOI":"10.1086\/650488","volume":"50","author":"N Kamar","year":"2010","unstructured":"Kamar N et al (2010) Pegylated interferon-alpha for treating chronic hepatitis E virus infection after liver transplantation. Clin Infect Dis 50:e30\u2013e33. https:\/\/doi.org\/10.1086\/650488","journal-title":"Clin Infect Dis"},{"key":"15_CR32","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.clinre.2014.07.005","volume":"39","author":"N Kamar","year":"2015","unstructured":"Kamar N et al (2015) Hepatitis E virus: chronic infection, extra-hepatic manifestations, and treatment. Clin Res Hepatol Gastroenterol 39:20\u201327. https:\/\/doi.org\/10.1016\/j.clinre.2014.07.005","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"15_CR33","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1128\/AAC.01795-13","volume":"58","author":"Y Debing","year":"2014","unstructured":"Debing Y et al (2014) Ribavirin inhibits in vitro hepatitis E virus replication through depletion of cellular GTP pools and is moderately synergistic with alpha interferon. Antimicrob Agents Chemother 58:267\u2013273. https:\/\/doi.org\/10.1128\/AAC.01795-13","journal-title":"Antimicrob Agents Chemother"},{"key":"15_CR34","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1007\/s00467-018-3905-7","volume":"33","author":"SE Cordts","year":"2018","unstructured":"Cordts SE et al (2018) Prevalence, morbidity, and therapy of hepatitis E virus infection in pediatric renal allograft recipients. Pediatr Nephrol 33:1215\u20131225. https:\/\/doi.org\/10.1007\/s00467-018-3905-7","journal-title":"Pediatr Nephrol"},{"key":"15_CR35","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.13411","volume":"32","author":"F Darstein","year":"2018","unstructured":"Darstein F et al (2018) Hepatitis E virus genotype 3 is a common finding in liver-transplanted patients undergoing liver biopsy for elevated liver enzymes with a low De Ritis ratio and suspected acute rejection: a real-world cohort. Clin Transpl 32:e13411. https:\/\/doi.org\/10.1111\/ctr.13411","journal-title":"Clin Transpl"},{"key":"15_CR36","doi-asserted-by":"publisher","first-page":"789","DOI":"10.2217\/fmb-2016-0012","volume":"11","author":"MT Perez-Gracia","year":"2016","unstructured":"Perez-Gracia MT et al (2016) Hepatitis E: latest developments in knowledge. Future Microbiol 11:789\u2013808. https:\/\/doi.org\/10.2217\/fmb-2016-0012","journal-title":"Future Microbiol"},{"key":"15_CR37","doi-asserted-by":"publisher","DOI":"10.5812\/jjm.26645","volume":"9","author":"S Shayanpour","year":"2016","unstructured":"Shayanpour S, Hayati F (2016) Hepatitis E virus infection among chronic hemodialysis. Jundishapur J Microbiol 9:e26645. https:\/\/doi.org\/10.5812\/jjm.26645","journal-title":"Jundishapur J Microbiol"},{"key":"15_CR38","doi-asserted-by":"publisher","first-page":"479","DOI":"10.7326\/0003-4819-155-7-201110040-00017","volume":"155","author":"HR Dalton","year":"2011","unstructured":"Dalton HR et al (2011) Treatment of chronic hepatitis E in a patient with HIV infection. Ann Intern Med 155:479\u2013480. https:\/\/doi.org\/10.7326\/0003-4819-155-7-201110040-00017","journal-title":"Ann Intern Med"},{"key":"15_CR39","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a031872","volume":"9","author":"N Kamar","year":"2019","unstructured":"Kamar N, Pischke S (2019) Acute and persistent hepatitis E virus genotype 3 and 4 infection: clinical features, pathogenesis, and treatment. Cold Spring Harb Perspect Med 9:a031872. https:\/\/doi.org\/10.1101\/cshperspect.a031872","journal-title":"Cold Spring Harb Perspect Med"},{"key":"15_CR40","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1053\/j.gastro.2016.05.060","volume":"152","author":"MC Donnelly","year":"2017","unstructured":"Donnelly MC et al (2017) Sofosbuvir and daclatasvir anti-viral therapy fails to clear HEV viremia and restore reactive T cells in a HEV\/HCV co-infected liver transplant recipient. Gastroenterology 152:300\u2013301. https:\/\/doi.org\/10.1053\/j.gastro.2016.05.060","journal-title":"Gastroenterology"},{"key":"15_CR41","doi-asserted-by":"publisher","first-page":"463","DOI":"10.3851\/IMP3227","volume":"23","author":"E Todesco","year":"2018","unstructured":"Todesco E et al (2018) Chronic hepatitis E in a heart transplant patient: sofosbuvir and ribavirin regimen not fully effective. Antivir Ther 23:463\u2013465. https:\/\/doi.org\/10.3851\/IMP3227","journal-title":"Antivir Ther"},{"key":"15_CR42","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.jhep.2019.03.029","volume":"71","author":"M Schulz","year":"2019","unstructured":"Schulz M et al (2019) Combination therapy of sofosbuvir and ribavirin fails to clear chronic hepatitis E infection in a multivisceral transplanted patient. J Hepatol 71:225\u2013227. https:\/\/doi.org\/10.1016\/j.jhep.2019.03.029","journal-title":"J Hepatol"},{"key":"15_CR43","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.jhep.2016.09.014","volume":"66","author":"M van der Valk","year":"2017","unstructured":"van der Valk M et al (2017) Sofosbuvir shows antiviral activity in a patient with chronic hepatitis E virus infection. J Hepatol 66:242\u2013243. https:\/\/doi.org\/10.1016\/j.jhep.2016.09.014","journal-title":"J Hepatol"},{"key":"15_CR44","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s15010-018-1168-7","volume":"46","author":"E Biliotti","year":"2018","unstructured":"Biliotti E et al (2018) Autochthonous acute hepatitis E: treatment with sofosbuvir and ribavirin. Infection 46:725\u2013727. https:\/\/doi.org\/10.1007\/s15010-018-1168-7","journal-title":"Infection"},{"key":"15_CR45","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1002\/hep.30428","volume":"69","author":"M Drinane","year":"2019","unstructured":"Drinane M, Jing Wang X, Watt K (2019) Sofosbuvir and ribavirin eradication of refractory hepatitis E in an immunosuppressed kidney transplant recipient. Hepatology 69:2297\u20132299. https:\/\/doi.org\/10.1002\/hep.30428","journal-title":"Hepatology"},{"key":"15_CR46","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1159\/000444468","volume":"34","author":"HR Dalton","year":"2016","unstructured":"Dalton HR et al (2016) Hepatitis E virus: time to change the textbooks. Dig Dis 34:308\u2013316. https:\/\/doi.org\/10.1159\/000444468","journal-title":"Dig Dis"},{"key":"15_CR47","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1517\/14728222.2015.1056155","volume":"19","author":"SP Kenney","year":"2015","unstructured":"Kenney SP, Meng XJ (2015) Therapeutic targets for the treatment of hepatitis E virus infection. Expert Opin Ther Targets 19:1245\u20131260. https:\/\/doi.org\/10.1517\/14728222.2015.1056155","journal-title":"Expert Opin Ther Targets"},{"key":"15_CR48","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.3748\/wjg.v22.i22.5143","volume":"22","author":"R Taherkhani","year":"2016","unstructured":"Taherkhani R, Farshadpour F (2016) Epidemiology of hepatitis E virus in Iran. World J Gastroenterol 22:5143\u20135153. https:\/\/doi.org\/10.3748\/wjg.v22.i22.5143","journal-title":"World J Gastroenterol"},{"issue":"1","key":"15_CR49","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jhep.2015.02.023","volume":"62","author":"U Beuers","year":"2015","unstructured":"Beuers U, Trauner M, Jansen P, Poupon R (2015) New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond. J Hepatol 62(1):25\u201337","journal-title":"J Hepatol"},{"key":"15_CR50","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1007\/s40265-021-01545-7","volume":"81","author":"S Hasegawa","year":"2021","unstructured":"Hasegawa S et al (2021) Cholestatic liver disease: current treatment strategies and new therapeutic agents. Drugs 81:1181\u20131192. https:\/\/doi.org\/10.1007\/s40265-021-01545-7","journal-title":"Drugs"},{"key":"15_CR51","doi-asserted-by":"publisher","first-page":"adv00653","DOI":"10.2340\/actadv.v102.310","volume":"102","author":"C Dervout","year":"2022","unstructured":"Dervout C et al (2022) Efficacy of treatments for cholestatic pruritus: a systemic review and meta-analysis. Acta Derm Venereol 102:adv00653. https:\/\/doi.org\/10.2340\/actadv.v102.310","journal-title":"Acta Derm Venereol"},{"key":"15_CR52","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.725993","volume":"8","author":"J Wu","year":"2021","unstructured":"Wu J et al (2021) Immunological manifestations of hepatitis E-associated acute and chronic liver failure and its regulatory mechanisms. Front Med 8:725993. https:\/\/doi.org\/10.3389\/fmed.2021.725993","journal-title":"Front Med"},{"key":"15_CR53","first-page":"253","volume":"38","author":"Chinese Society of Hepatology, Chinese Medical Association","year":"2022","unstructured":"Chinese Society of Hepatology, Chinese Medical Association (2022) Guideline on the management of cholestasis liver diseases. J Hepatol 38:253\u2013263","journal-title":"J Hepatol"},{"key":"15_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2021.100255","volume":"3","author":"AJ Sanyal","year":"2021","unstructured":"Sanyal AJ et al (2021) Potent suppression of hydrophobic bile acids by aldafermin, an FGF19 analogue, across metabolic and cholestatic liver diseases. JHEP Rep 3:100255. https:\/\/doi.org\/10.1016\/j.jhepr.2021.100255","journal-title":"JHEP Rep"},{"key":"15_CR55","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1111\/apt.13309","volume":"42","author":"H Blasco-Perrin","year":"2015","unstructured":"Blasco-Perrin H et al (2015) Hepatitis E virus in patients with decompensated chronic liver disease: a prospective UK\/French study. Aliment Pharmacol Ther 42:574\u2013581","journal-title":"Aliment Pharmacol Ther"},{"key":"15_CR56","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.jceh.2013.08.013","volume":"3","author":"A Kumar","year":"2013","unstructured":"Kumar A, Saraswat VA (2013) Hepatitis E and acute-on-chronic liver failure. J Clin Exp Hepatol 3:225\u2013230","journal-title":"J Clin Exp Hepatol"},{"key":"15_CR57","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.jcv.2012.01.016","volume":"54","author":"R Anty","year":"2012","unstructured":"Anty R et al (2012) First case report of an acute genotype 3 hepatitis E infected pregnant woman living in South-Eastern France. J Clin Virol 54:76\u201378","journal-title":"J Clin Virol"},{"key":"15_CR58","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/1743-422X-11-68","volume":"11","author":"C Renou","year":"2014","unstructured":"Renou C et al (2014) Prospective study of Hepatitis E Virus infection among pregnant women in France. Virol J 11:68","journal-title":"Virol J"},{"key":"15_CR59","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1111\/liv.14221","volume":"39","author":"Y Wang","year":"2019","unstructured":"Wang Y et al (2019) Incidence, predictors and prognosis of genotype 4 hepatitis E related liver failure: a tertiary nested case-control study. Liver Int 39:2291\u20132300. https:\/\/doi.org\/10.1111\/liv.14221","journal-title":"Liver Int"},{"key":"15_CR60","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s12879-022-07050-w","volume":"22","author":"JW Choi","year":"2022","unstructured":"Choi JW et al (2022) Acute hepatitis E virus superinfection increases mortality in patients with cirrhosis. BMC Infect Dis 22:62. https:\/\/doi.org\/10.1186\/s12879-022-07050-w","journal-title":"BMC Infect Dis"},{"key":"15_CR61","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1111\/jvh.13174","volume":"26","author":"J Wu","year":"2019","unstructured":"Wu J et al (2019) HEV-LFS: a novel scoring model for patients with hepatitis E virus-related liver failure. J Viral Hepat 26:1334\u20131343. https:\/\/doi.org\/10.1111\/jvh.13174","journal-title":"J Viral Hepat"},{"key":"15_CR62","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1093\/cid\/ciy234","volume":"67","author":"JC Lai","year":"2018","unstructured":"Lai JC et al (2018) Chronic Hepatitis B increases liver-related mortality of patients with acute hepatitis E: a territory wide cohort study from 2000 to 2016. Clin Infect Dis 67:1278\u20131284. https:\/\/doi.org\/10.1093\/cid\/ciy234","journal-title":"Clin Infect Dis"},{"key":"15_CR63","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2020.593674","volume":"10","author":"H Fan","year":"2020","unstructured":"Fan H et al (2020) Prognostic significance of end-stage liver diseases, respiratory tract infection, and chronic kidney diseases in symptomatic acute hepatitis E. Front Cell Infect Microbiol 10:593674. https:\/\/doi.org\/10.3389\/fcimb.2020.593674","journal-title":"Front Cell Infect Microbiol"},{"key":"15_CR64","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/j.jhep.2016.12.003","volume":"66","author":"European Association for the Study of the Liver","year":"2017","unstructured":"European Association for the Study of the Liver (2017) EASL clinical practical guidelines on the management of acute (fulminant) liver failure. J Hepatol 66:1047\u20131081. https:\/\/doi.org\/10.1016\/j.jhep.2016.12.003","journal-title":"J Hepatol"},{"key":"15_CR65","first-page":"38","volume":"35","author":"Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association, Severe Liver Disease and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association","year":"2018","unstructured":"Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association, Severe Liver Disease and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association (2018) Guideline for diagnosis and treatment of liver failure. J Clin Hepatol 35:38\u201344","journal-title":"J Clin Hepatol"},{"key":"15_CR66","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1080\/00365521.2021.1899277","volume":"56","author":"M Madsen","year":"2021","unstructured":"Madsen M, Kimer N, Bendtsen F, Petersen AM (2021) Fecal microbiota transplantation in hepatic encephalopathy: a systematic review. Scand J Gastroenterol 56:560\u2013569. https:\/\/doi.org\/10.1080\/00365521.2021.1899277","journal-title":"Scand J Gastroenterol"},{"key":"15_CR67","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.00376-21","volume":"89","author":"G Ancona","year":"2021","unstructured":"Ancona G et al (2021) The interplay between gut microbiota and the immune system in liver transplant recipients and its role in infections. Infect Immun 89:e0037621. https:\/\/doi.org\/10.1128\/IAI.00376-21","journal-title":"Infect Immun"},{"key":"15_CR68","first-page":"73","volume":"7","author":"A Shresha","year":"2017","unstructured":"Shresha A, Gupta BP, Lama TK (2017) Current treatment of acute and chronic hepatitis E virus infection: role of antivirals. Euroasian J Hepatogastroenter 7:73\u201377","journal-title":"Euroasian J Hepatogastroenter"},{"key":"15_CR69","first-page":"328","volume":"6","author":"JM Peron","year":"2013","unstructured":"Peron JM, Abravanel F, Guillaume M et al (2013) Treatment of autochthonous acute hepatitis E with short\u2014term ribavirin: a multicenter retrospective study. Liver Int 6:328\u2013333","journal-title":"Liver Int"},{"key":"15_CR70","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1111\/liv.12911","volume":"36","author":"JM Peron","year":"2016","unstructured":"Peron JM, Abravanel F, Guillaume M et al (2016) Treatment of autochthonous acute hepatitis E with short\u2014term ribavirin: a multicenter retrospective study. Liver Int 36:328\u2013333","journal-title":"Liver Int"},{"key":"15_CR71","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40506-020-00235-4","volume":"2020","author":"P Kar","year":"2020","unstructured":"Kar P, Karna R (2020) A review of the diagnosis and management of hepatitis E. Curr Treat Options Infect Dis 2020:1\u201311. https:\/\/doi.org\/10.1007\/s40506-020-00235-4","journal-title":"Curr Treat Options Infect Dis"},{"key":"15_CR72","doi-asserted-by":"publisher","first-page":"5904","DOI":"10.3748\/wjg.v19.i35.5904","volume":"19","author":"SH Cheng","year":"2013","unstructured":"Cheng SH et al (2013) Influence of chronic HBV infection on superimposed acute hepatitis E. World J Gastroenterol 19:5904\u20135909. https:\/\/doi.org\/10.3748\/wjg.v19.i35.5904","journal-title":"World J Gastroenterol"},{"key":"15_CR73","doi-asserted-by":"publisher","first-page":"2792","DOI":"10.1093\/ndt\/gfq282","volume":"25","author":"N Kamar","year":"2010","unstructured":"Kamar N et al (2010) Three-month pegylated interferon-alpha-2a therapy for chronic hepatitis E virus infection in a haemodialysis patient. Nephrol Dial Transplant 25:2792\u20132795. https:\/\/doi.org\/10.1093\/ndt\/gfq282","journal-title":"Nephrol Dial Transplant"},{"key":"15_CR74","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1002\/hep.29694","volume":"67","author":"RT Stravitz","year":"2018","unstructured":"Stravitz RT et al (2018) Bleeding complications in acute liver failure: liver failure\/cirrhosis\/portal hypertension. Hepatology 67:1931\u20131942. https:\/\/doi.org\/10.1002\/hep.29694","journal-title":"Hepatology"},{"key":"15_CR75","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1016\/j.jhep.2020.07.013","volume":"73","author":"CF Rose","year":"2020","unstructured":"Rose CF et al (2020) Hepatic encephalopathy: Novel insights into classification, pathophysiology and therapy. J Hepatol 73:1526\u20131547. https:\/\/doi.org\/10.1016\/j.jhep.2020.07.013","journal-title":"J Hepatol"},{"key":"15_CR76","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/S2468-1253(16)30157-1","volume":"2","author":"A Facciorusso","year":"2017","unstructured":"Facciorusso A, Chandar AK, Murad MH et al (2017) Comparative efficacy of pharmacological strategies for management of type 1 hepatorenal syndrome: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol 2:94\u2013102. https:\/\/doi.org\/10.1016\/S2468-1253(16)30157-1","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"15_CR77","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1053\/j.gastro.2016.02.026","volume":"150","author":"TD Boyer","year":"2016","unstructured":"Boyer TD, Sanyal AJ, Wong F et al (2016) Terlipressin plus albumin is more effective than albumin alone in improving renal function in patients with cirrhosis and hepatorenal syndrome type 1. Gastroenterology 150:1579\u20131589. https:\/\/doi.org\/10.1053\/j.gastro.2016.02.026","journal-title":"Gastroenterology"},{"issue":"Suppl 1","key":"15_CR78","first-page":"10","volume":"70","author":"F Wong","year":"2019","unstructured":"Wong F, Curry M, Reddy R et al (2019) LO5 The CONFIRM study: a North American randomized controlled trial (RCT) of terlipressin plus albumin for the treatment of hepatorenal syndrome type 1 (HRS-1). Hepatology 70(Suppl 1):10","journal-title":"Hepatology"},{"key":"15_CR79","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1002\/hep.30208","volume":"71","author":"V Arora","year":"2020","unstructured":"Arora V, Maiwall R, Rajan V et al (2020) Terlipressin is superior to noradrenaline in the management of acute kidney injury in acute on chronic liver failure. Hepatology 71:600\u2013610. https:\/\/doi.org\/10.1002\/hep.30208","journal-title":"Hepatology"},{"key":"15_CR80","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1056\/NEJMra2021808","volume":"384","author":"JS Bajaj","year":"2021","unstructured":"Bajaj JS, Kamath PS, Reddy KR (2021) The evolving challenge of infections in cirrhosis. N Engl J Med 384:2317\u20132330","journal-title":"N Engl J Med"},{"key":"15_CR81","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1056\/NEJMoa1703058","volume":"376","author":"CW Seymour","year":"2017","unstructured":"Seymour CW, Gesten F, Prescott HC et al (2017) Time to treatment and mortality during mandated emergency care for sepsis. N Engl J Med 376:2235\u20132244","journal-title":"N Engl J Med"},{"key":"15_CR82","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1136\/gutjnl-2017-314240","volume":"67","author":"J Fernandez","year":"2017","unstructured":"Fernandez J, Acevedo J, Wiest R et al (2017) Bacterial and fungal infections in acute-on-chronic liver failure: prevalence, characteristics and impact on prognosis. Gut 67:1870\u20131880","journal-title":"Gut"},{"issue":"Suppl 1","key":"15_CR83","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1111\/liv.13645","volume":"38","author":"S Piano","year":"2018","unstructured":"Piano S, Brocca A, Mareso S et al (2018) Infections complicating cirrhosis. Liver Int 38(Suppl 1):126\u2013133","journal-title":"Liver Int"},{"key":"15_CR84","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1097\/MCC.0b013e328344b3aa","volume":"17","author":"TI Hassanein","year":"2011","unstructured":"Hassanein TI, Schade RR, Hepburn IS (2011) Acute-on-chronic liver failure: extracorporeal liver assist devices. Curr Opin Crit Care 17:195\u2013203","journal-title":"Curr Opin Crit Care"},{"key":"15_CR85","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.ccc.2016.03.003","volume":"32","author":"CJ Karvellas","year":"2016","unstructured":"Karvellas CJ, Subramanian RM (2016) Current evidence for extracorporeal liver support systems in acute liver failure and acute-on-chronic liver failure. Crit Care Clin 32:439\u2013451","journal-title":"Crit Care Clin"},{"key":"15_CR86","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1097\/MCC.0000000000000584","volume":"25","author":"FS Larsen","year":"2019","unstructured":"Larsen FS (2019) Artificial liver support in acute and acute-on-chronic liver failure. Curr Opin Crit Care 25:187\u2013191. https:\/\/doi.org\/10.1097\/MCC.0000000000000584","journal-title":"Curr Opin Crit Care"},{"issue":"5","key":"15_CR87","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/j.jhep.2016.01.011","volume":"64","author":"L Allweiss","year":"2016","unstructured":"Allweiss L, Gass S, Giersch K, Groth A, Kah J, Volz T et al (2016) Human liver chimeric mice as a new model of chronic hepatitis E virus infection and preclinical drug evaluation. J Hepatol 64(5):1033\u20131040. https:\/\/doi.org\/10.1016\/j.jhep.2016.01.011","journal-title":"J Hepatol"},{"issue":"1","key":"15_CR88","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1053\/j.gastro.2015.09.011","volume":"150","author":"VL Dao Thi","year":"2016","unstructured":"Dao Thi VL, Debing Y, Xianfang W, Rice CM, Neyts J, Moradpour D et al (2016) Sofosbuvir Inhibits hepatitis E virus replication in vitro and results in an additive effect when combined with ribavirin. Gastroenterology 150(1):82\u201385 e84. https:\/\/doi.org\/10.1053\/j.gastro.2015.09.011","journal-title":"Gastroenterology"},{"issue":"12","key":"15_CR89","doi-asserted-by":"publisher","first-page":"2866","DOI":"10.1111\/liv.15033","volume":"41","author":"G Sari","year":"2021","unstructured":"Sari G, Mulders CE, Jingting Z, Oord GW, Zongdi F, Kreeft-Voermans JJC et al (2021) Treatment induced clearance of hepatitis E viruses by interferon-lambda in liver-humanized mice. Liver Int 41(12):2866\u20132873. https:\/\/doi.org\/10.1111\/liv.15033","journal-title":"Liver Int"},{"issue":"6","key":"15_CR90","doi-asserted-by":"publisher","first-page":"485","DOI":"10.3390\/v11060485","volume":"11","author":"V Kinast","year":"2019","unstructured":"Kinast V, Burkard TL, Todt D, Steinmann E (2019) Hepatitis E virus drug development. Viruses 11(6):485. https:\/\/doi.org\/10.3390\/v11060485","journal-title":"Viruses"},{"issue":"4","key":"15_CR91","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.jhep.2019.06.005","volume":"71","author":"CF Soon","year":"2019","unstructured":"Soon CF, Behrendt P, Todt D, Manns MP, Wedemeyer H, Chen MS et al (2019) Defining virus-specific CD8+ TCR repertoires for therapeutic regeneration of T cells against chronic hepatitis E. J Hepatol 71(4):673\u2013684. https:\/\/doi.org\/10.1016\/j.jhep.2019.06.005","journal-title":"J Hepatol"}],"container-title":["Advances in Experimental Medicine and Biology","Hepatitis E Virus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-981-99-1304-6_15","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T07:09:54Z","timestamp":1684912194000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-981-99-1304-6_15"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"ISBN":["9789819913039","9789819913046"],"references-count":91,"URL":"https:\/\/doi.org\/10.1007\/978-981-99-1304-6_15","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"value":"0065-2598","type":"print"},{"value":"2214-8019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023]]},"assertion":[{"value":"25 May 2023","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}